Zydus Lifesciences

Global Healthcare Cost Containment Will Erode Premium Margins

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Nov 24

Updated

24 Sep 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-6.4%

7D

-1.2%

Loading

1Y

-6.4%

7D

-1.2%

You can edit this narrative until Sep 25 10:20 AM. Then, changes will post as Updates.

Author's Valuation

₹1.02k8.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 24 Sep 25

Fair value Increased 1.08%

The upward revision in Zydus Lifesciences’ consensus revenue growth forecast from 6.1% to 6.5% has supported a slight increase in the Analyst Price Target to ₹1018. What's in the News Entered into an exclusive licensing and supply agreement with Synthon BV for the U.S. commercialization of generic Ozanimod Capsules (ZEPOSIA), with eligibility for shared 180-day market exclusivity pending FDA approval.

Shared on 04 Sep 25

As consensus analyst forecasts for Zydus Lifesciences’ revenue growth and future P/E remained virtually unchanged, the fair value estimate also held steady at ₹1007. What's in the News Zydus Therapeutics reported positive topline results for Saroglitazar in the EPICS-III Phase 2(b)/3 trial for Primary Biliary Cholangitis, meeting both primary and secondary endpoints; a US regulatory submission is planned for early 2026, and the drug has Orphan Drug and Fast Track Designations from the USFDA.

Shared on 01 May 25

Fair value Decreased 8.26%

Shared on 23 Apr 25

Fair value Decreased 0.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.49%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹1.02k

8.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

7.42%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹42.43b

Earnings '28

x

34.56x

PE Ratio '28

=

₹1.47t

Market Cap '28

₹1.47t

Market Cap '28

/

1.01b

No. shares '28

=

₹1.46k

Share Price '28

₹1.46k Share Price '28

Discounted to 2025 @ 12.73% p.a.

=

₹1.02k

Fair Value '25